Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. V: Manufacture and quality control

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. V: Manufacture and quality control

Chimeric antigen receptor T cells (CAR-T), especially against CD19 marker, present in lymphomas and acute B leukemia, enabled a revolution in the treatment of hematologic neoplastic diseases. The manufacture of CAR-T cells requires the adoption of GMP-compatible methods and it demands the collection...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gil Cunha De Santis, Dante Mário Langhi Junior, Andreza Feitoza, Alfredo Mendrone Junior, José Mauro Kutner, Dimas Tadeu Covas, Samuel Campanelli Freitas Couto, Renato L. Guerino-Cunha, Maristela Delgado Orellana, Sílvia Renata Cornelio Parolin Rizzo
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Adoptive cellular immunotherapy
CAR-T cell therapy
Cryopreservation
Quality control
Diseases of the blood and blood-forming organs
RC633-647.5
Acceso en línea:https://doaj.org/article/a0bd95033e124bd38e266ed79eec3c57
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares